Minneapolis, MN, USA and Paris, France and Munich, Germany, 9 July 2026 – TRiCares SAS (“TRiCares”), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, today announces that the first patient has been enrolled and treated in the TRICURE US IDE pivotal study, evaluating Topaz, its Transcatheter Tricuspid Valve Replacement (TTVR) system. This enrollment marks the first randomized controlled study to actively enroll patients in a head-to-head comparison of an investigational TTVR system versus the commercially available Edwards EVOQUE™ TTVR system.